Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Small Molecule Therapeutics

Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy

Li-Hsien Chen, Yuan-Ting Sun, Yih-Fung Chen, Mei-Yi Lee, Lian-Yun Chang, Jang-Yang Chang and Meng-Ru Shen
Li-Hsien Chen
1Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuan-Ting Sun
2Department of Neurology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
3Department of Internal Medicine, National Cheng Kung University Hospital Dou-Liou Branch, Yunlin, Taiwan.
4Advanced Optoelectronic Technology Center, National Cheng Kung University, Tainan, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yih-Fung Chen
1Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
5Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mei-Yi Lee
1Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lian-Yun Chang
1Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jang-Yang Chang
6Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
7National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meng-Ru Shen
1Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
4Advanced Optoelectronic Technology Center, National Cheng Kung University, Tainan, Taiwan.
8Obstetrics and Gynecology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mrshen@mail.ncku.edu.tw
DOI: 10.1158/1535-7163.MCT-15-0268 Published October 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Chemotherapy-induced neurotoxicity is a common adverse effect of cancer treatment. No medication has been shown to be effective in the prevention or treatment of chemotherapy-induced neurotoxicity. This study aimed to discover potential neuroprotective drugs for paclitaxel-induced neurotoxicity. An image-based high-content platform was first developed to screen for potential neuroprotective drugs. The screening system comprised of automated image acquisition and multiparameter analysis, including neuronal viability, neurite outgrowth, and synaptogenesis. By this platform, we obtained a candidate list from compound libraries. In the drug screening from compound libraries of ion channel ligands, REDOX and GABAergic ligands, 5-hydroxydecanoate (5-HD) exhibited the most significant neuroprotective effects against paclitaxel-induced neurotoxicity in both cortical and dorsal root ganglion (DRG) neurons. In mouse behavioral tests, 5-HD restored the thermal sensitivity and alleviated mechanical allodynia induced by paclitaxel. Electron micrographs of sciatic nerve revealed that 5-HD reduced the damages caused by paclitaxel in the nonmyelinated and smaller myelinated fibers. The mechanistic study on DRG neurons suggested that 5-HD rescued the dysregulation of intracellular calcium homeostasis provoked by paclitaxel. Importantly, 5-HD did not jeopardize the antitumor effect of paclitaxel in tumor xenograft models. In conclusion, we established an imaged-based high-content screening platform and a protocol for verifying the neuroprotective effect in vivo, by which 5-HD was identified and validated as a potential neuroprotective drug for paclitaxel-induced neuropathy. Mol Cancer Ther; 14(10); 2206–14. ©2015 AACR.

This article is featured in Highlights of This Issue, p. 2165

Introduction

Advances in cancer therapy have increased the number of cancer patients who live disease free for long periods. However, a considerable proportion of cancer survivors experience the side effects of chemotherapy. Neurotoxicity is a common complication in cancer patients receiving chemotherapy. The clinical symptoms are in a wide range, including numbness, unsteadiness, and chronic pain. These symptoms not only jeopardize the quality of life but also lead to early discontinuation of anticancer treatment (1–3). Effective neuroprotective drugs against chemotherapy are not available so far. The development of appropriate preclinical assay models and objective assessments of chemotherapy-associated neurotoxicity are thus critical steps to test potential therapies for toxic reduction or prevention.

Current strategies for evaluating chemical-induced neurotoxicity include in vitro examination of morphologic and functional changes in neurons, and in vivo assessment of neuropathologic and behavioral endpoints in rodent species (4). As animal behavioral studies are high-priced, time-consuming, labor-intensive, and low-throughput processes, the cell-based in vitro neurotoxicity assays are much easier to screen out toxic compounds in a high-throughput manner at the early stage of drug development. However, several shortages are noted in most in vitro studies, including irrelevant cell models, insufficient analytic parameters, and subjective image selections. For example, the easily handled and rapidly growing cancerous neuroblastoma or nonneuronal pheochromocytoma cells are usually used to study neuron survival and neurite outgrowth (1). These cancer cell lines cannot truly represent normal neurons due to their distinct signal pathways, gene expressions, and cellular responses to stimuli (5, 6). Although human stem cell–derived neural hN2™ cells have been reported to be more sensitive to neurite outgrowth inhibitors, they showed a wide range of variability, compared with primary neuron cultures (7, 8).

Regarding the analytic parameters, previous studies mostly applied neuron viability and neurite outgrowth for neurotoxicity and paid less attention to synapses (8, 9). However, the synapse is the basic element for neural network formation and is worth being included in a complete assessment of neural functions because it represents a specialized axon–dendrite contact site mediating neurotransmitter-based communication (10). Synaptic plasticity and integrity in the central nervous system (CNS) are important in pain perception and cognitive function (11, 12). The loss of synaptic function and the neural network have been reported in the presence of chemotherapy agents. For example, paclitaxel-induced hyperalgesia negatively modulates affective pain and synaptic function in the rat frontal cortex (13). Moreover, the throughput of image acquisition and analysis is the key to study cellular or subcellular changes in neurons, but to date most studies have depended on the manual selection of representative images and lack standardized quantitative analyses, which leads to selection bias. Therefore, the high-content screening strategies combined with automated image acquisition and analyses are essential for the establishment of efficient in vitro neurotoxic assays.

This study aims to develop an image-based high-content platform and a mouse model for the discovery of potential neuroprotective drugs against chemotherapy. Using this high-content platform to screen compounds from drug libraries of ion channel ligands, REDOX (portmanteau of reduction and oxidation), and GABAergic ligands, we identified 5-hydroxydecanoate (5-HD) as a novel neuroprotective drug against paclitaxel-induced neurotoxicity. More importantly, the mouse behavioral tests validated the effectiveness of 5-HD in preventing and treating paclitaxel-induced neuropathy.

Materials and Methods

Compounds

Compounds listed in Supplementary Table S1 were from ENZO Life Sciences. Paclitaxel and liposomal doxorubicin were gifts from Bristol-Myers Squibb and TTY Biopharm, respectively. Cisplatin and vincristine were purchased from Sigma-Aldrich.

Primary cortical neuron and dorsal root ganglion cultures

Brain cortices were microdissected from post-natal day 0 C57BL/6J mouse pups, incubated with trypsin (Caisson) for 5 minutes. Minced cortical neuron mixtures were filtered, centrifuged, and resuspended in neurobasal medium designed for long-term viability of neurons, supplemented with B-27 supplement (Gibco), 0.5 mmol/L l-glutamine, and 0.5% penicillin–streptomycin (Caisson). Dorsal root ganglion (DRG) was removed from adult female C57BL/6J mice at 7 weeks old and the tissues digested with 0.1% collagenase (Sigma) for 1 hour, followed by 0.25% trypsin for 25 minutes. The dissociated mixed neuron cultures were plated at a density of 2.8 × 104 cells per well in a 96-well thin-bottom optic microplate (Costar) precoated with 1 mg/mL poly-d-lysine (Sigma-Aldrich) for the indicated time period.

Immunofluorescence and automated image acquisition

Cells were fixed with 4% paraformaldehyde for 15 minutes, washed with 0.05% Triton X-100 in PBS for 30 minutes, and blocked with 3% bovine serum albumin (Sigma-Aldrich) at room temperature for 1 hour. Then, cells were stained with primary antibody at 4°C overnight, washed by PBS and stained with secondary antibodies at room temperature for 1 hour. Information on antibodies is presented in Supplementary Table S2. Cell images were automatically acquired using a 20× objective with 0.75 numerical aperture and Hi-resolution mode (1×1 pixel binning) by an ImageXpressMicro automated wide-field fluorescent microscope (Molecular Devices).

Animal behavioral tests and drug administration

Female C57BL/6J mice, ages 7 weeks at the beginning of the experiment, were used for studying paclitaxel-induced neuropathy. Paclitaxel (4.5 mg/kg), vehicle (saline), or 5-HD (5 or 10 mg/kg) was injected intraperitoneally on four alternative days (days 0, 2, 4, and 6), as previously described (14). The baseline measurement of each test was taken prior to paclitaxel or vehicle administration, and five additional sessions of tests were recorded weekly for 5 weeks. Paw withdrawal by the von Frey filament test was assessed by electronic von Frey hairs (Part #2390; IITC Instruments). Heat hypersensitivity of tail withdrawal was measured by the tail immersion assay. Motor function impairment was measured by the grip strength test. The detailed information on animal tests is described in Supplementary Materials and Methods.

Ultrastructure of the sciatic nerve

Following mouse behavioral tests at the last time point, sciatic nerve samples were collected, fixed in 4% glutaraldehyde, and post-fixed in 1% osmium tetroxide. The samples were dehydrated through a graded ethanol series, embedded in EMbed 812 (EMS; #14120), and sliced into 90 nm thick sections. After ultrathin sectioning, the sciatic nerve samples were observed and imaged with a transmission electron microscope (H7650, Hitachi).

Intracellular [Ca2+]i measurement

DRGs were isolated at the sixth week after behavioral tests and cultured for 4 days for the measurement of intracellular Ca2+ concentration ([Ca2+]i) at 37°C with the Fura-2 fluorescence ratio method on a single-cell fluorimeter as previously described (15). The Fura-2 was excited alternatively between 340 and 380 nm using the Polychrome IV monochromator (Till Photonics). The fluorescence intensity at 510 nm was analyzed, and [Ca2+]i was calculated using TILLvisION 4.0 (Till Photonics; ref. 15). Detailed information on the [Ca2+]i measurement is described in Supplementary Materials and Methods.

Tumor xenograft model

The cervical cancer SiHa cell line was prepared as previously described (15). The cell line was authenticated by the short-tandem repeats analysis using the Promega StemElite ID System (GeneLabs Life Science Corp). In the animal model, 2 × 106 cervical cancer SiHa cells were inoculated subcutaneously into the basolateral flank of 10-week-old female NOD/SCID mice. Two weeks after implantation, mice were randomized to receive the different therapies. Body weight and tumor size were measured every other day. Tumor volume (mm3) was calculated by using the formula: 1/2 × (the shortest tumor diameter)2 × (the longest tumor diameter) (15). Two weeks later, mice were sacrificed and tumors were isolated for weighing.

Statistical analysis

Data are expressed as mean ± SEM. Differences between groups were compared using the Student t test or one-way ANOVA followed by the Bonferroni post-test. The criterion for statistical significance was P < 0.05.

Results

The strategies of drug discovery

We first designed the protocol for drug development to include 5 steps (Supplementary Fig. S1). Step 1, establish a high-content image-based screening platform to study the central nervous system (CNS) and peripheral nervous system (PNS), respectively; step 2, screen lead compounds for neuroprotection; step 3, validate the neuroprotective effects in a mouse model of chemotherapy-induced neurotoxicity; step 4, study the effect of lead compounds on anticancer therapy; step 5, determine the mechanism of the protective effect.

For the cell model, cortical neurons from postnatal day 0 pups or DRG neurons from adult female mice at 7 weeks old were cultured in 96-well plates, fixed and stained for the automated image acquisition and analyses (Supplementary Fig. S2). About 200 micrographs in each well were taken to create a montage image showing the entire neural network. The neuron-specific microtubule-associated protein 2 (MAP2) antibody, a somatodendritic marker, was applied to visualize the cell body and extending processes of a cortical neuron, enabling the generation of a binary mask of neuronal morphology for the automated image analyses. To pick out a cortical neuron accurately from the mixed culture, the expected nuclear size of MAP2-positive cells was entered into the computer program. The specificity of MAP2 antibody for neurons was validated in the primary mixed cultures (Supplementary Fig. S3). Morphologic parameters, such as cell body, processes, branches, and synaptic puncta in cortical neuronal culture were defined (Supplementary Fig. S2B). These measurements represent the vitality, growth, and formation of functional units of cortical neurons. To optimize the in vitro culture period, the postnatal mouse cortical neurons were cultured for 7, 10, 14, and 21 days in vitro (DIV) and a binary mask of neuronal cell body and processes was obtained (Fig. 1A, a2–d2). Synaptic puncta were obtained through the detection of synaptophysin staining (Fig. 1A, a3–d3). Quantified data shown in Fig. 1B display the control cell neural viability (neuron numbers) and synaptogenesis (synaptic puncta number per neuron) at 10 DIV. Morphologic parameters associated with neurite outgrowth, such as process number, process length, neurite length, and branch number also reached a plateau at 10 DIV (Fig. 1C). Therefore, 10 DIV is the optimal time point to assess CNS neuronal function in this image-based system. In the cell model of PNS, anti-NeuN and anti-beta III tubulin antibodies were applied to visualize the cell body and extending processes of DRG neurons, enabling the generation of a binary mask of neuronal morphology for the automated image analysis (Supplementary Fig. S2C).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Representative images of MAP2- and synaptophysin-labeled developing neurons. A, mouse cortical neurons were cultivated for 7, 10, 14, and 21 days in vitro (DIV), and then stained with anti-MAP2 (green), anti-synaptophysin antibodies (red), and Hoechst 33258 (blue). Selected neuron images were enlarged, further segmented, and automatically analyzed by applying the computational modules of neurite outgrowth (a1–d1). The white pseudocolor mask in a2–d2 indicates the area of neuronal cell body and the extending neurite process and branching junction. Synaptic puncta spatially associated with a MAP2-stained neuron are shown in a3–d3 by using the combined computational modules of synapse counting and cell scoring in the analysis software of MetaXpress (Molecular Devices). Scale bar, 50 μm. B and C, various measured neuronal parameters in 7, 10, 14, and 21 DIV neurons. B, a graph of neuron number and synaptogenesis. x axis, postnatal DIV; y axis, detected neuron number per well (left). y axis, number of synaptic puncta per neuron (right). C, the quantification of process number, process length, neurite length, and branch number. x axis, postnatal DIV; left y axis, all data were normalized to the 7 DIV values. Data, mean ± SEM. All graphs and data in B and C were obtained from 5 independent experiments.

Neurotoxic profiles of paclitaxel

By the screening platform, we studied the in vitro neurotoxicity of paclitaxel (Fig. 2A and B). Paclitaxel was incubated with primary cultures of cortical or DRG neurons for 24 hours at therapeutic ranges (16). Figure 2 shows the dose–response curves of neurotoxicity in terms of neuron viability, synaptic puncta formation, and neurite outgrowth. Paclitaxel at the therapeutic concentration of 1 μmol/L (17) inhibited about 75% and 30% of neurite outgrowth in DRG and cortical neurons, respectively (Fig. 2A and B). This implies that paclitaxel has a prominent neurotoxicity on PNS, compared with a lesser toxic effect on CNS neurons. This is consistent with clinical observations on paclitaxel-induced peripheral neuropathy (16).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Neurotoxicity of paclitaxel. Dose–response curves of neurotoxic effects of paclitaxel on primary cortical neurons (A) and DRG neurons (B). Primary neurons were incubated with paclitaxel at therapeutic concentrations for 24 hours. All data were normalized to the control group. Y axis, the normalized ratio; x axis, the concentration of paclitaxel. Dose–response curves of neurotoxic effects of cisplatin, vincristine, and liposomal doxorubicin on viability (C), synaptogenesis (D), and neurite outgrowth of primary cortical neurons (E). Primary neurons were incubated with chemotherapy drugs at the therapeutic concentrations for 24 hours. All data were normalized to the control group. Y axis, the normalized ratio; x axis, the concentration of drugs. Data, mean ± SEM from at least three different experiments.

After testing the neurotoxic effect of paclitaxel on primary cortical neurons, we also used this neuron-based screening platform to study the neurotoxicity of commonly prescribed chemotherapeutic drugs including cisplatin, vincristine, and liposomal doxorubicin. Among these drugs, vincristine showed the prominent toxicity on neuron viability, neurite outgrowth, and synaptic formation (Fig. 2C–E). In contrast, liposomal doxorubicin displayed less neurotoxic profiles of these parameters (Fig. 2C–E).

High-content screening of potential neuroprotective agents against paclitaxel-induced neurotoxicity

We further used paclitaxel as a neurotoxic drug to screen for potential neuroprotective agents from compound libraries (Supplementary Table S1). To test neuroprotective effects, primary cortical neurons isolated from P0 mouse pups were pretreated with various concentrations of compounds for 24 hours and then exposed to paclitaxel for another 24 hours. In the pilot screening from 213 compounds, 8 candidates, including 5-hydroxydecanoate (5-HD), amiloride, glyburide, gingerol, minoxidil sulfate, chlormezanone, hinokitiol, and propyl gallate showed a significant neuroprotective effect against paclitaxel, with regard to synaptogenesis, neurite outgrowth, and viability in cortical neurons (Fig. 3A and B and Supplementary Fig. S4A).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Neuroprotective drugs screened from the image-based high-content platform. A, to test neuroprotective effects, primary cortical neurons isolated from P0 mouse pups were pretreated with various concentrations of compounds for 24 hours and then exposed to 1.0 μmol/L paclitaxel for another 24 hours. In the pilot screening, 8 candidates, including 5-hydroxydecanoate (5-HD, 1 μmol/L), amiloride (0.01 μmol/L), glyburide (1 μmol/L), gingerol (0.01 μmol/L), minoxidil sulfate (1 μmol/L), chlormezanone (1 μmol/L), hinokitiol (1 μmol/L), and propyl gallate (1 μmol/L) showed a significant neuroprotective effect against paclitaxel (1 μmol/L) with regard to neurite outgrowth, synaptogenesis, and viability in cortical neurons. Each value represents the mean ± SEM from at least 3 different experiments. #, P < 0.05; *, P < 0.01; **P < 0.001, compared with the paclitaxel-treated group, by unpaired t test. B, representative images show that 5-HD is a potential neuroprotective drug in the cell model of cortical neurons. *, neuron body; arrow, synaptic puncta; arrow head, neurite outgrowth. Scale bar, 50 μm. Green, MAP2; red, synaptophysin; blue, Hoechst. C, eight candidates, including 5-HD, amiloride, glyburide, gingerol, minoxidil sulfate, chlormezanone, hinokitiol, and propyl gallate showed a significant neuroprotective effect against paclitaxel (1 μmol/L) in the model of DRG neurons. Each value represents the mean ± SEM from at least 3 different experiments. #, P < 0.05; *P < 0.01; **, P < 0.001, compared with the paclitaxel-treated group, by unpaired t test. D, representative images show that 5-HD is a potential neuroprotective drug in the cell model of DRG neurons. Green, anti-β-III tubulin antibody; red, anti-NeuN antibody. Scale bar, 50 μm. *, neuron body; arrow head, neurite outgrowth.

We also studied the potential protective effects of 8 hit compounds on DRG neurons, the main source of neuron damage in chemotherapy-induced peripheral neuropathy (Fig. 3C). Compared with the control group, the paclitaxel-treated DRG neurons showed about a 75% decrease in neurite outgrowth. The 8 hit compounds, which were selected from the screening in the CNS model, showed variable neuroprotective effects on neurite outgrowth of DRG neurons (Fig. 3C). Among them, pretreatment with 1 μmol/L 5-HD rescued around 40% of the damage in neurite outgrowth caused by paclitaxel (Fig. 3C and D). Taking the data from central and peripheral neurons together, 1 μmol/L 5-HD exhibited the most significant neuroprotective effects against paclitaxel-induced neurotoxicity.

The neuroprotective effects of 5-HD in vivo

To validate the neuroprotective effects of 5-HD, a mouse model of paclitaxel-induced neuropathy was applied (14, 18). At first, we did a preliminary experiment to determine the effective concentrations of 5-HD in the mouse model, and 10 mg/kg 5-HD was shown to be the maximum safe dose. Subsequently, C57BL/6J female mice were pretreated with a safe dose of 5-HD (5 or 10 mg/kg) 1 hour prior to each injection of paclitaxel (4.5 mg/kg) over 7 days. Afterwards, the mouse behavioral tests, including tail immersion study, von Frey filament test, and grip test were conducted weekly to assess the thermal threshold, mechanical allodynia, and motor function, respectively (Fig. 4A). The paclitaxel-treated mice exhibited an increase of thermal threshold (Fig. 4B) and a dramatic drop of mechanical threshold (Fig. 4C), consistent with previous studies in mouse models (14). Pretreatment with 5-HD enabled the mice to regain their thermal sensitivity (Fig. 4B) and alleviated mechanical allodynia (Fig. 4C). The grip strength was not affected by paclitaxel (Supplementary Fig. S5), consistent with clinical observations that paclitaxel predominantly affects sensory fibers instead of motor function (19). The post hoc analysis of data obtained at the post-treatment 5th week showed significant protective effects of 5-HD on paclitaxel-induced sensory deficits (Fig. 4B and C, right plane).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

The neuroprotective effects of 5-HD in a mouse model. A, protocol showing drug administration and behavioral tests in the mouse model. The basal levels of each behavioral assay were obtained prior to the drug treatment. In the first week, 4.5 mg/kg paclitaxel (PTX) was injected intraperitoneally every other day and 5 or 10 mg/kg 5-HD was administrated by intraperitoneal injection one hour prior to paclitaxel treatment. After four courses of treatment, behavioral tests were done weekly. B, tail immersion test to assess thermal sensation (left). Y axis, normalized latency from tail immersion to tail withdrawal. Quantitative analyses of tail immersion at the 5th week (right). Each value represents mean ± SEM from at least 10 mice in each group. *, P < 0.05; ***, P < 0.001. C, von Frey filament test to detect allodynia (left). Y axis, normalized pressure from touch to paw withdrawal. Quantitative analyses of von Frey filament test at the 5th week (right). Each value represents mean ± SEM from at least 10 mice in each group. **, P < 0.01; ***, P < 0.001. D–F, no adverse effect of 5-HD on the anticancer treatment of paclitaxel in the NOD/SCID mouse model of human cervical cancer xenografts. D, growth curves of human cervical cancer xenografts in various groups. Control group, n = 6; paclitaxel group, n = 5; 5-HD group, n = 5. 5-HD + paclitaxel group, n = 5. Each value represents mean ± SEM. *, P < 0.05; ***, P < 0.001. E, tumor xenograft isolated from NOD/SCID mice at the 5th week. Scale bar, 1 cm. F, the tumor weight of xenograft. Each value represents mean ± SEM. **, P < 0.01, by one-way ANOVA, post hoc analysis.

We also designed experiments to study whether 5-HD could reverse paclitaxel-induced neurotoxicity. 5-HD was administered after neuropathy was induced and mouse behavior tests were performed (Supplementary Fig. S6). Two weeks after paclitaxel injection, the mice exhibited an increase of thermal threshold (Supplementary Fig. S6B) and a significant decrease of mechanical threshold (Supplementary Fig. S6C). 5-HD partially alleviated mechanical allodynia (Supplementary Fig. S6C) but showed no effect on thermal sensitivity (Supplementary Fig. S6B).

No adverse effect of 5-HD on antitumor treatment

To test whether 5-HD alters tumor growth in vivo, we inoculated NOD/SCID mice subcutaneously with human cervical cancer SiHa cells. Paclitaxel and 5-HD were administrated according to the protocol shown in Fig. 4A. As depicted in Fig. 4D, rapid tumor growth was obvious in the control groups. In contrast, treatment with paclitaxel inhibited tumor growth. 5-HD itself did not change the tumor growth and it also did not affect the antitumor effect of paclitaxel (Fig. 4D–F).

Histology of sciatic nerve

The ultrastructure of nerve tissues was studied at the 6th week after paclitaxel treatment (protocol as Fig. 4A). Paclitaxel causes nerve damage both to myelinated and nonmyelinated fibers (Fig. 5A), in which nerve tissues show a varying degree of dying axons (black arrow in Fig. 5A), vacuolized Schwann cells, detached compact myelin with accumulated myelin debris (white dashed arrow in Fig. 5A and B), and multiple swollen and vacuolated mitochondria in the axons (black dashed arrow in Fig. 5A and C). In contrast, 5-HD treatment displayed similar pathologies of nerve but with less severity (Fig. 5A–D).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Ultrastructure of mouse sciatic nerve. A, transmission electron microscopy (TEM) images. Paclitaxel-induced sciatic nerve damage includes dying axons (black arrow), myelin debris (white dashed arrow), and swollen intra-axonal mitochondria (black dashed arrow). N, nucleus of Schwann cell. Scale bar, 1 μm. B, G ratio measurement in the sciatic nerves: the ratio of axon circumference (white solid line). The G ratio of small fibers (axon diameter < 5 μm) and large fibers (axon diameter >5 μm) in mouse sciatic nerves from the four groups are presented. **, P < 0.01; ***, P < 0.001, by unpaired t test. C, representative TEM images show that paclitaxel caused swollen and vacuolated mitochondria (atypical mitochondria). Scale bar, 1 μm. D, quantitative analyses of atypical mitochondria indicate that 5-HD can prevent some of the mitochondrial damage caused by paclitaxel. Each value represents mean ± SEM of at least 150 mitochondria. **, P < 0.01, by unpaired t test.

We also assessed the integrity of myelination by the G-ratio, a ratio of axon circumference to myelin circumference. The micrographs (Fig. 5B are representative) show representative images of myelinated fibers in which the axon (white circle) and myelin circumference (white dashed line) are indicated. Axons were further grouped by axon sizes. In small fibers (axon diameter < 5 μm), G-ratio was decreased by paclitaxel, but could be significantly rescued by 5-HD treatment (P < 0.001, Fig. 5B). On the other hand, the G-ratio of large fibers was not significantly affected by paclitaxel (Fig. 5B). This result indicates that paclitaxel tends to affect smaller fibers, consistent with clinical observation indicating that paclitaxel-induced neurotoxicity predominantly affects sensory fibers (20).

5-HD protects DRG neurons by remodeling [Ca2+]i homeostasis

We further studied the protective mechanism of 5-HD. Paclitaxel has been shown to disturb intracellular Ca2+ ([Ca2+]i) homeostasis, which contributes to peripheral neuropathy (21). The process of store-operated Ca2+ entry (SOCE), whereby Ca2+ influx across the plasma membrane is activated in response to depletion of intracellular Ca2+ stores in the endoplasmic reticulum, actively participates in [Ca2+]i homeostasis and potentially plays a significant role in pain pathologies (22). Accordingly, we measured the SOCE of DRG neurons in various conditions. DRG neurons from mice that have undergone behavioral tests with or without 5-HD treatment were isolated and cultured for [Ca2+]i measurement (Fig. 6A). As shown in Fig. 6B, the pretreatment of 5-HD significantly eliminated the paclitaxel-induced damage to neurite outgrowth of DRG neurons. In the [Ca2+]i measurement of DRG neurons, the magnitude of Ca2+ influx induced by reintroduction of Ca2+ following thapsigargin-induced endoplasmic reticulum (ER) store depletion (SOCE) was downregulated by paclitaxel. In contrast, 5-HD moderately upregulated SOCE, which significantly prevented the decreased SOCE induced by paclitaxel (Fig. 6C and D). This implies that the protective effect of 5-HD on peripheral neurons is likely due to the maintenance of [Ca2+]i homeostasis.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

5-HD protects DRG neurons by remodeling [Ca2+]i homeostasis. A, protocol showing drug administration and behavioral tests in mouse models. DRG were isolated at the 6th week and cultured for 4 days for image studies and intracellular Ca2+ ([Ca2+]i) measurement. B, representative images of neurite outgrowth of DRG neurons isolated at the 6th week. Cell body and neurites were labeled with anti-NeuN and anti-β-III tubulin antibodies, respectively. Scale bar, 50 μm. C and D, representative [Ca2+]i measurement and quantitative analyses of SOCE amplitude in DRG neurons isolated at the 6th week. Mean traces of [Ca2+]i measurement from at least 20 different DRG neurons in each experiment. 0–2 mmol/L following depletion of ER-Ca2+ stores by thapsigargin treatment. D, y axis, quantitative analyses of SOCE changes in Ca2+ level (Δ[Ca2+]i). Each value represents mean ± SEM of at least 20 DRG neurons. Arrow, adding 2 μmol/L thapsigargin (TG). **, P < 0.01; ***, P < 0.001 by unpaired t test. SOCE: Store-operated Ca2+ entry.

Discussion

Here, we established an optimal protocol for drug discovery to prevent paclitaxel-induced neurotoxicity, including a drug screening platform, validation experiments, mouse models for behavioral tests and tumor xenografts. A mixed cortical neuron-dominant culture and a DRG culture were used in our cell-based screening platform. These primary neuron cultures mimic the true environment of the nervous system and solve the complicated dedifferentiation issue of immortalized cell lines. The image-based high-content screening platform with automatic image acquisition and analysis overcomes the shortages of insufficient analytic parameters and image selection bias noted in previous studies.

Paclitaxel is a standard treatment for breast, cervical, ovarian, and lung cancer (23). The incidence of paclitaxel-induced neuropathy ranges from 20% to 70% of patients (24, 25). Mechanisms include disruption of axonal transport (26, 27), mitochondrial damage (28–30), altered ion channel activities (31), and neuronal inflammation (32, 33). Here we screened three compound libraries, including ion channel ligands, GABA and REDOX libraries, for the discovery of potential neuroprotective drugs. In the pilot screening, 5-HD showed potential protective effects on paclitaxel-induced neurotoxicity. This conclusion was supported by the following evidence: (i) 5-HD rescued paclitaxel-induced damage to neurite outgrowth in DRG neurons and the viability, neurite outgrowth and synaptogenesis in cortical neurons; (ii) 5-HD restored the thermal sensitivity and alleviated mechanical allodynia in paclitaxel-treated mice; (iii) the histopathology and quantified G ratio of myelin integrity of nerve tissue isolated from 5-HD/paclitaxel-treated mice supported the observations in mouse behavioral tests; (iv) 5-HD rescued paclitaxel-induced DRG damage in vitro and in vivo.

5-HD is a mitochondrial ATP-sensitive K+ channel (mitoKATP channel) antagonist. The mitoKATP channel regulates both internal Ca2+ concentration and the inner membrane potential upon the onset of cellular energy crisis (34). Chronic paclitaxel treatments have been reported to decrease Ca2+ signaling (14, 35) and impair SOCE (36), which is related to peripheral neuropathy (37). Our data showing that pretreatment with 5-HD significantly reversed the paclitaxel-induced decreases in SOCE implying that 5-HD may prevent chemotherapy-induced peripheral neuropathy by restoring [Ca2+]i homeostasis in DRG neurons. The neuroprotective effect of 5-HD was shown previously in models of aging-related neurodegenerative disease, in which 5-HD reduced angiotensin II-induced cell death in dopaminergic neurons (38). In the vascular system, 5-HD prevented the development of pulmonary hypertension by inhibiting TGF-β1 or MCP-1 signaling pathway (39). Fatty acids are abundant in the brain and are important in neuronal membrane biosynthesis, energy metabolism and even nociceptive transmission (40–42). 5-HD has been reported to be a substrate for acyl-CoA synthetase, which activates fatty acids (43). This raises the possibility of another neuroprotective mechanism of 5-HD in paclitaxel-induced neurotoxicity, that of regulating fatty acid metabolism.

Conclusion

This study describes a feasible, reliable modular image-based high-content screening platform. Combined with in vivo validation studies in mouse models, we found a promising lead, 5-HD, that can potentially prevent and alleviate paclitaxel-induced neuropathy. It ameliorated paclitaxel-induced neurotoxicity by restoring [Ca2+]i homeostasis in DRG neurons, and did not jeopardize the antitumor effect of paclitaxel. Early pharmacokinetic and metabolic evaluations in animal models are the immediate next steps planned for preclinical studies. Future efforts will be made to discover other neuroprotective agents by this well-established screening platform.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: Y.-T. Sun, M.-R. Shen

Development of methodology: L.-H. Chen, Y.-T. Sun, M.-Y. Lee, L.-Y. Chang, M.-R. Shen

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L.-H. Chen, Y.-F. Chen, M.-Y. Lee, L.-Y. Chang, M.-R. Shen

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L.-H. Chen, Y.-T. Sun, M.-Y. Lee, M.-R. Shen

Writing, review, and/or revision of the manuscript: Y.-T. Sun, Y.-F. Chen, M.-Y. Lee, M.-R. Shen

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L.-H. Chen, Y.-F. Chen, L.-Y. Chang, J.-Y. Chang, M.-R. Shen

Study supervision: M.-R. Shen

Grant Support

This work was supported by the Ministry of Science and Technology, Taiwan (to J.Y. Chang and M.R. Shen), and the National Cheng Kung University, Taiwan (to J.Y. Chang and M.R. Shen).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

The authors thank the Bio-image Core Facility of the National Core Facility Program for Biotechnology, Ministry of Science and Technology, Taiwan, for technical services.

Footnotes

  • Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

  • Received April 1, 2015.
  • Revision received July 29, 2015.
  • Accepted July 30, 2015.
  • ©2015 American Association for Cancer Research.

References

  1. 1.↵
    1. Radio NM,
    2. Breier JM,
    3. Shafer TJ,
    4. Mundy WR
    . Assessment of chemical effects on neurite outgrowth in PC12 cells using high content screening. Toxicol Sci 2008;105:106–18.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Dropcho EJ
    . Neurotoxicity of cancer chemotherapy. Semin Neurol 2010;30:273–86.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Grisold W,
    2. Cavaletti G,
    3. Windebank AJ
    . Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012;14:iv45–54.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Coecke S,
    2. Goldberg AM,
    3. Allen S,
    4. Buzanska L,
    5. Calamandrei G,
    6. Crofton K,
    7. et al.
    Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies. Environ Health Perspect 2007;115:924–31.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Harrill JA,
    2. Freudenrich TM,
    3. Robinette BL,
    4. Mundy WR
    . Comparative sensitivity of human and rat neural cultures to chemical-induced inhibition of neurite outgrowth. Toxicol Appl Pharmacol 2011;256:268–80.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Gotte M,
    2. Hofmann G,
    3. Michou-Gallani AI,
    4. Glickman JF,
    5. Wishart W,
    6. Gabriel D
    . An imaging assay to analyze primary neurons for cellular neurotoxicity. J Neurosci Methods 2010;192:7–16.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. LePage KT,
    2. Dickey RW,
    3. Gerwick WH,
    4. Jester EL,
    5. Murray TF
    . On the use of neuro-2a neuroblastoma cells versus intact neurons in primary culture for neurotoxicity studies. Crit Rev Neurobiol 2005;17:27–50.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Sharp DJ,
    2. Yu W,
    3. Ferhat L,
    4. Kuriyama R,
    5. Rueger DC,
    6. Baas PW
    . Identification of a microtubule-associated motor protein essential for dendritic differentiation. J Cell Biol 1997;138:833–43.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Caceres A,
    2. Banker GA,
    3. Binder L
    . Immunocytochemical localization of tubulin and microtubule-associated protein 2 during the development of hippocampal neurons in culture. J Neurosci 1986;6:714–22.
    OpenUrlAbstract
  10. 10.↵
    1. Harrill JA,
    2. Robinette BL,
    3. Mundy WR
    . Use of high content image analysis to detect chemical-induced changes in synaptogenesis in vitro. Toxico In Vitro 2011;25:368–87.
    OpenUrlCrossRef
  11. 11.↵
    1. Luo C,
    2. Kuner T,
    3. Kuner R
    . Synaptic plasticity in pathological pain. Trends Neurosci 2014;37:343–55.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Mastellos DC
    . Complement emerges as a masterful regulator of CNS homeostasis, neural synaptic plasticity and cognitive function. Exp Neurol 2014;261:469–74.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Noda K,
    2. Akita H,
    3. Ogata M,
    4. Saji M
    . Paclitaxel-induced hyperalgesia modulates negative affective component of pain and NR1 receptor expression in the frontal cortex in rats. Neurosci Res 2014;80:32–7.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Mo M,
    2. Erdelyi I,
    3. Szigeti-Buck K,
    4. Benbow JH,
    5. Ehrlich BE
    . Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment. FASEB J 2012;26:4696–709.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Chen YF,
    2. Chiu WT,
    3. Chen YT,
    4. Lin PY,
    5. Huang HJ,
    6. Chou CY,
    7. et al.
    Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. Proc Natl Acad Sci U S A 2011;108:15225–30.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Carlson K,
    2. Ocean AJ
    . Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer 2011;11:73–81.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Scripture CD,
    2. Szebeni J,
    3. Loos WJ,
    4. Figg WD,
    5. Sparreboom A
    . Comparative in vitro properties and clinical pharmacokinetics of paclitaxel following the administration of Taxol® and Paxene®. Cancer Biol Ther 2005;4:555–60
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Saha L,
    2. Hota D,
    3. Chakrabarti A
    . Evaluation of lercanidipine in Paclitaxel-induced neuropathic pain model in rat: a preliminary study. Pain Res Treat 2012;2012:143579.
    OpenUrlPubMed
  19. 19.↵
    1. Tofthagen C,
    2. McAllister RD,
    3. Visovsky C
    . Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptoms. J Adv Pract Oncol 2013;4:204–15.
    OpenUrlPubMed
  20. 20.↵
    1. Swain SM,
    2. Arezzo JC
    . Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008;6:455–67.
    OpenUrlPubMed
  21. 21.↵
    1. Benbow JH,
    2. Mann T,
    3. DeGray B,
    4. Ehrlich BE
    . Protection against paclitaxel induced decreases in calcium signaling. Toxicology 2012;286:34575–82
    OpenUrl
  22. 22.↵
    1. Alkhani H,
    2. Ase AR,
    3. Grant R,
    4. O'Donnell D,
    5. Groschner K,
    6. Seguela P
    . Contribution of TRPC3 to store-operated calcium entry and inflammatory transductions in primary nociceptors. Mol Pain 2014;10:43.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Wani MC,
    2. Taylor HL,
    3. Wall ME,
    4. Coggon P,
    5. McPhail AT
    . Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325–7.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Argyriou AA,
    2. Koltzenburg M,
    3. Polychronopoulos P,
    4. Papapetropoulos S,
    5. Kalofonos HP
    . Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008;66:218–28.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Lee JJ,
    2. Swain SM
    . Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24:1633–42.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Shemesh OA,
    2. Spira ME
    . Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta Neuropathol 2010;119:235–48.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. LaPointe NE,
    2. Morfini G,
    3. Brady ST,
    4. Feinstein SC,
    5. Wilson L,
    6. Jordan MA
    . Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 2013;37:231–9.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Zheng H,
    2. Xiao WH,
    3. Bennett GJ
    . Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011;232:154–61.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Flatters SJ,
    2. Bennett GJ
    . Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006;122:245–57.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Xiao WH,
    2. Bennett GJ
    . Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain 2012;153:704–9.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Hara T,
    2. Chiba T,
    3. Abe K,
    4. Makabe A,
    5. Ikeno S,
    6. Kawakami K,
    7. et al.
    Effect of paclitaxel on transient receptor potential vanilloid 1 in rat dorsal root ganglion. Pain 2013;154:882–9.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Peters CM,
    2. Jimenez-Andrade JM,
    3. Jonas BM,
    4. Sevcik MA,
    5. Koewler NJ,
    6. Ghilardi JR,
    7. et al.
    Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 2007;203:42–54.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Nishida K,
    2. Kuchiiwa S,
    3. Oiso S,
    4. Futagawa T,
    5. Masuda S,
    6. Takeda Y,
    7. et al.
    Up-regulation of matrix metalloproteinase-3 in the dorsal root ganglion of rats with paclitaxel-induced neuropathy. Cancer Sci 2008;99:1618–25.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Tinker A,
    2. Aziz Q,
    3. Thomas A
    . The role of ATP-sensitive potassium channels in cellular function and protection in the cardiovascular system. Br J Pharmacol 2014;171:12–23.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Boehmerle W,
    2. Zhang K,
    3. Sivula M,
    4. Heidrich FM,
    5. Lee Y,
    6. Jordt SE,
    7. et al.
    Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc Natl Acad Sci U S A 2007;104:11103–8.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Pan Z,
    2. Avila A,
    3. Gollahon L
    . Paclitaxel induces apoptosis in breast cancer cells through different calcium–regulating mechanisms depending on external calcium conditions. Int J Mol Sci 2014;15:2672–94.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Gemes G,
    2. Bangaru ML,
    3. Wu HE,
    4. Tang Q,
    5. Weihrauch D,
    6. Koopmeiners AS,
    7. et al.
    Store-operated Ca2+ entry in sensory neurons: functional role and the effect of painful nerve injury. J Neurosci 2011;31:3536–49.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Rodriguez-Pallares J,
    2. Parga JA,
    3. Joglar B,
    4. Guerra MJ,
    5. Labandeira-Garcia JL
    . Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease. Age 2012;34:863–80.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Dong L,
    2. Li Y,
    3. Hu H,
    4. Shi L,
    5. Chen J,
    6. Wang B,
    7. et al.
    Potential therapeutic targets for hypoxia-induced pulmonary artery hypertension. J Transl Med 2014;12:39.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Molino D,
    2. Galli T
    . Biogenesis and transport of membrane domains-potential implications in brain pathologies. Biochimie 2014;96:75–84.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Panov A,
    2. Orynbayeva Z,
    3. Vavilin V,
    4. Lyakhovich V
    . Fatty acids in energy metabolism of the central nervous system. Biomed Res Int 2014;2014:472459.
    OpenUrlPubMed
  42. 42.↵
    1. Piomelli D,
    2. Hohmann AG,
    3. Seybold V,
    4. Hammock BD
    . A lipid gate for the peripheral control of pain. J Neurosci 2014;34:15184–91.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Hanley PJ,
    2. Dröse S,
    3. Brandt U,
    4. Lareau RA,
    5. Banerjee AL,
    6. Srivastava DK,
    7. et al.
    5-Hydroxydecanoate is metabolised in mitochondria and creates a rate-limiting bottleneck for beta-oxidation of fatty acids. J Physiol 2005;562:307–18.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Molecular Cancer Therapeutics: 14 (10)
October 2015
Volume 14, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy
Li-Hsien Chen, Yuan-Ting Sun, Yih-Fung Chen, Mei-Yi Lee, Lian-Yun Chang, Jang-Yang Chang and Meng-Ru Shen
Mol Cancer Ther October 1 2015 (14) (10) 2206-2214; DOI: 10.1158/1535-7163.MCT-15-0268

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy
Li-Hsien Chen, Yuan-Ting Sun, Yih-Fung Chen, Mei-Yi Lee, Lian-Yun Chang, Jang-Yang Chang and Meng-Ru Shen
Mol Cancer Ther October 1 2015 (14) (10) 2206-2214; DOI: 10.1158/1535-7163.MCT-15-0268
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Efficacy of Rigosertib in Rhabdomyosarcoma and Neuroblastoma
  • Combination of AZD0364 and Selumetinib in KRAS-Mutant NSCLC
  • eFT226, a Selective Inhibitor of eIF4A-Mediated Translation
Show more Small Molecule Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement